These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Serum calcium, phosphate and alkaline phosphatase and morphometric bone examinations in 30 patients with renal insufficiency. Duursma SA; Visser WJ; Mees EJ; Njio L Calcif Tissue Res; 1974; 16(2):129-38. PubMed ID: 4447892 [No Abstract] [Full Text] [Related]
6. Comparison of 1 alpha-hydroxycholecalciferol and 25-hydroxycholecalciferol in the treatment of renal osteodystrophy: greater effect of 25-hydroxycholecalciferol on bone mineralization. Fournier A; Bordier P; Gueris J; Sebert JL; Marie P; Ferrière C; Bedrossian J; DeLuca HF Kidney Int; 1979 Feb; 15(2):196-204. PubMed ID: 513484 [No Abstract] [Full Text] [Related]
7. Serum hydroxyproline and renal osteodystrophy in patients maintained on haemodialysis. Goulding A; McChesney R; Irvine RO; Dixon SR N Z Med J; 1974 Dec; 80(530):540-4. PubMed ID: 4615274 [No Abstract] [Full Text] [Related]
8. 1,25-dihydroxycholecalciferol in patients with chronic renal failure. Henderson RG; Ledingham JG; Norman AW; Oliver DO; Preston C; Russell RG; Small DG; Smith R; Warner GT; Woods CG Proc Eur Dial Transplant Assoc; 1973; 10(0):202-9. PubMed ID: 4802654 [No Abstract] [Full Text] [Related]
9. [Variations in serum levels of phosphorus (iP), calcium (Ca), calcitonin (iCT) and parathormone (iPTH) in patients under periodic hemodialysis. Effects of exogenous calcitonin therapy]. Bucciante G; Bernardi A; Biasia F; Milan G; Donato D Minerva Med; 1985 Mar; 76(9-10):415-7. PubMed ID: 3982698 [No Abstract] [Full Text] [Related]
13. A possible role for propranolol in the treatment of renal osteodystrophy. Caro JF; Besarab A; Burke JF; Glennon JA Lancet; 1978 Aug; 2(8087):451-4. PubMed ID: 79809 [TBL] [Abstract][Full Text] [Related]
14. [Renal osteopathy and bone mineralisation in patients treated with dihydrotachysterol during long term dialysis (author's transl)]. Pogglitsch H; Schmidberger H; Gell G MMW Munch Med Wochenschr; 1976 Jan; 118(5):131-6. PubMed ID: 814443 [TBL] [Abstract][Full Text] [Related]
15. [Evaluation of terminal parathormone NH2 and COOH and plasma calcitonin in the blood of uremic patients under hemodialysis therapy]. Di Landro D; Zanatta GP; Simioni N; Pinzani A; Zotti D; Perin N; Bertoli M; Naso A; Ruffatti A; Gasparotto ML Minerva Med; 1985 Mar; 76(9-10):419-23. PubMed ID: 3982699 [No Abstract] [Full Text] [Related]
16. PTH and bone markers of renal osteodystrophy in predialysis chronic renal failure. Coen G; Mazzaferro S; Ballanti P; Bonucci E J Endocrinol Invest; 1992; 15(9 Suppl 6):129-33. PubMed ID: 1300330 [No Abstract] [Full Text] [Related]
17. 1alpha-hydroxycholecalciferol and 25-hydroxycholecalciferol in renal bone disease. Fournier AE; Bordier PJ; Gueris J; Chanard J; Marie P; Ferriere C; Osario M; Bedrossian J; De Luca HF Calcif Tissue Res; 1976 Aug; 21 Suppl():226-35. PubMed ID: 782662 [No Abstract] [Full Text] [Related]
18. A case of renal osteodystrophy with unexpected serum intact parathyroid hormone concentrations. Meany DL; Jan de Beur SM; Bill MJ; Sokoll LJ Clin Chem; 2009 Sep; 55(9):1737-9. PubMed ID: 19717659 [No Abstract] [Full Text] [Related]
19. Effect of CKD-MBD phenotype on health-related quality of life in patients receiving maintenance hemodialysis: A cross-sectional study. Luo L; Chen Q J Int Med Res; 2020 Feb; 48(2):300060519895844. PubMed ID: 32054360 [TBL] [Abstract][Full Text] [Related]